Direct Compression of 5 mg Finasteride Cores at Production Scale

Manufacturing of the 5 mg immediate-release tablet for symptomatic benign prostatic hyperplasia is anchored to the compendial monograph for finasteride tablets and requires a deliberate low-dose blending sequence rather than single-stage bin blending. The API is dispensed in a segregated weigh room under 21 CFR 211.80 and 21 CFR 211.84, and the incoming material is released only after identity, assay, chromatographic purity, residual solvents per ICH Q3C, and elemental impurities per ICH Q3D are verified. A typical core formulation uses 120–180 mg total weight, placing the finasteride mass fraction at 2.8–4.2% w/w; excipients include lactose monohydrate NF or microcrystalline cellulose NF as diluents, crospovidone NF at 2–4% w/w as disintegrant, and magnesium stearate NF at 0.25–1.0% w/w as lubricant. The production sequence begins with pre-blending the API with 5–10 parts of diluent through a 30-mesh screen, followed by a larger pre-blend in a low-shear tumble mixer, then transfer to a 150–600 L bin blender operated at 10–20 rpm for 15–25 min. Lubricant is added as a final pass through the blender for 3–5 min; over-lubrication beyond 1.0% w/w or extended blending above 25 min can retard dissolution and increase tablet friability. Compression is performed on a rotary tablet press with a force feeder, main compression force 8–15 kN, precompression force 2–5 kN, and turret speed 30–70 rpm; tablet hardness is typically maintained at 5–10 kp, with friability not exceeding 1.0% per USP <1216>. In-process controls follow 21 CFR 211.110, and the final release includes content uniformity per USP <905>, dissolution per USP <711>, and chromatographic purity. The terminal finished dosage type is a film-coated 5 mg tablet, with aqueous or solvent-based coating applied in a perforated pan coater at inlet air 60–70 °C, exhaust air 40–48 °C, atomising air 1.0–2.0 bar, and a coating weight gain of 3–6% w/w. Operational boundaries include replacing API and excipient container closures immediately after dispensing when ambient relative humidity exceeds 60%, because micronized finasteride and low-moisture lactose can adsorb surface moisture and shift magnesium stearate distribution during compression.

The 1 mg finasteride tablet for androgenetic alopecia imposes a content-uniformity risk profile that differs from the 5 mg dose in one critical respect: the API mass fraction in an 80–120 mg core falls to 0.83–1.25% w/w, so segregation after final blend discharge becomes the dominant failure mode rather than granule over-wetting or cap capping. Because the acceptance value for dosage-unit uniformity under USP <905> is 15.0, the blend must be validated not only for mean assay but also for location-to-location variability after transfer from the 150–600 L bin blender to the tablet press hopper. Production-scale batch records show that electrostatic adhesion of micronized API to grounded stainless-steel bin walls can deplete the discharged blend by 2–5% relative assay in the final 5–10 kg portion if the bin is not fitted with a split-valve discharge and if the blend is not held at 40–70% bin fill. A common formulation uses lactose monohydrate NF and microcrystalline cellulose NF as diluents, crospovidone NF at 1–3% w/w, magnesium stearate NF at 0.25–0.75% w/w, and optionally colloidal silicon dioxide NF at 0.1–0.3% w/w to reduce hopper bridging. The API is first triturated with 5–10 parts of the diluent and passed through a 40-mesh screen; if the API particle size distribution contains an oversize fraction above the validation range, a co-milling step with lactose monohydrate in a cone mill at 1500–3000 rpm is used instead of direct packing of the raw powder. Compression is performed on a rotary press with a force feeder paddle speed set to 30–50% of maximum; main compression force is kept at 6–12 kN because the lower tablet weight requires less compaction work and higher force can increase friability at the edges. Tablet hardness is maintained at 3–8 kp, and disintegration time is monitored as an in-process test to remain below 15 min in water at 37 °C. Release testing includes USP <905>, USP <711>, USP <1216>, 21 CFR 211.165, and a dissolution method using a surfactant-containing medium because finasteride is practically insoluble in water; the exact medium, apparatus, and Q value are fixed by the compendial monograph for finasteride tablets. The terminal finished dosage type is a 1 mg film-coated tablet, and the coating step uses a perforated pan coater with inlet air 60–70 °C, exhaust air 40–48 °C, atomising air 1.0–2.0 bar, and a 3–6% w/w coating weight gain. Operational boundaries include avoiding direct bag-to-press transfer of the lubricated blend, avoiding blend hold times beyond 30 min in an unfluidised hopper, and avoiding compression at ambient relative humidity above 60% unless the suite is controlled and the API is discharged through a split valve under low differential pressure.

Why Does Encapsulation Require Trituration Before the Capsule Fill Step?

Hard gelatin and HPMC capsule presentation of finasteride at 0.5–5.0 mg per unit is not a first-line commercial dosage form in most jurisdictions but appears in compounding practice and early-phase clinical trial material, where the low dose and poor aqueous solubility demand a geometric dilution protocol before the powder is loaded into a capsule machine. The formulation addition ratio is defined as 0.5–5.0 mg finasteride in a fill weight of 100–300 mg, corresponding to an API mass fraction of 0.17–5.0% w/w depending on capsule size and clinical dose. Compliance in the United States for compounded oral capsules is anchored to USP <795>, with batch release including visual uniformity, weight variation, and finished-product assay; when the same formulation is produced under investigational drug GMP, 21 CFR 211.80, 211.110, and 211.165 apply, and impurity limits are controlled against ICH Q3D for elemental impurities and ICH Q3C for residual solvents. The downstream production process begins with dry trituration of the API with lactose monohydrate NF in a porcelain or stainless-steel mortar using a 1:5 to 1:10 geometric dilution ratio until no visible API specks remain; the triturate is passed through a 60-mesh screen, then blended with the remaining lactose, optional colloidal silicon dioxide NF at 0.2–0.5% w/w, and magnesium stearate NF at 0.25–0.5% w/w in a 5–50 L V-blender or low-shear tumble mixer for 10–20 min. In semi-automatic capsule filling, size 3 or size 4 capsules are filled by weight with periodic weight checks; in automatic dosator-type encapsulation, the powder bed depth is controlled at 5–15 mm and the tamping pin pressure is set to avoid over-compaction that can delay capsule dissolution. The main process conflict is powder flow: finasteride-lactose blends without a glidant can bridge in the capsule hopper at fill weights below 150 mg, leading to weight variation above ±5% RSD; adding colloidal silicon dioxide above 0.5% w/w reduces flow but can also lower dissolution, so the formulation is adjusted by tapped-density measurement rather than fixed excipient ratio. The terminal finished dosage type is a hard gelatin or HPMC capsule containing 0.5–5.0 mg of finasteride; the choice of HPMC capsules is documented for vegetarian or halal markets where gelatin is unacceptable. Published data for this specific configuration is limited outside compounding practice and small-scale clinical batches, so dissolution method transfer from the tablet monograph must be verified with a discriminating medium rather than assumed from the tablet product.

A granulated finasteride intermediate for oral suspension or sachet filling is prepared when dysphagia, enteral-tube administration, or individualised dosing requires a dispersible solid rather than a film-coated tablet; published data for this specific configuration is limited outside compounding and clinical trial records. The formulation addition ratio is 1–5 mg finasteride per 1.0–2.0 g finished granule fill, corresponding to an API mass fraction of 0.05–0.5% w/w, with a diluent base of sucrose or mannitol rather than a compressed tablet diluent because granule dispersibility controls the reconstitution profile. Compliance for nonsterile compounding follows USP <795>; for registered granules, 21 CFR 211.110 in-process sampling and USP <905> uniformity of unit-dose sachets apply. The downstream process uses wet granulation in a high-shear granulator: finasteride is pre-dispersed in a portion of the diluent by geometric dilution, then wet-massed with a binder solution of povidone K30 at 5–10% w/w solids; the wet mass is granulated to an impeller torque endpoint, transferred to a fluid-bed dryer with inlet air 45–60 °C, and dried to a loss-on-drying of 1.0–2.5% w/w. The dried granules are sized through an 18-mesh screen and collected above a 60-mesh screen; fines below 60-mesh are limited to 10–20% w/w because excess fines segregate during sachet filling and reduce reconstitution homogeneity. The final granule is filled into stick packs or sachets on a volumetric filler with weight control at ±5% RSD; the fill weight is re-calculated from tapped density because granule particle size distribution shifts after every dryer discharge. The terminal finished dosage type is a unit-dose sachet or stick pack containing granules for reconstitution into an oral suspension, typically dispersed in 30–60 mL of water immediately before administration; the reconstituted suspension is not a solution and must be agitated until dispersed. Operational boundaries include avoiding sucrose-based granulation at ambient relative humidity above 65% because hygroscopic sucrose can cake in the filler, and avoiding wet-massing time beyond the torque endpoint because over-granulation produces oversized granules that fail to disperse within 60 s of stirring.

When Finasteride Is Compounded as a Sterile Intralesional Solution

Sterile injectable finasteride for intralesional alopecia management is not an FDA-approved finished product in the United States and lacks a harmonised compendial monograph; however, compounding pharmacies preparing it under USP <797> operate within a defined aseptic framework because the drug substance is practically insoluble in water and must be solubilised in a cosolvent or cyclodextrin-based vehicle. The formulation addition ratio is typically 0.25–1.0 mg/mL finasteride in a vehicle of 10–30% v/v propylene glycol and 5–20% v/v ethanol with water for injection qs; cyclodextrin-based vehicles may replace alcohol-containing vehicles where alcohol avoidance is clinically required, but published data for this specific configuration is limited. The production process begins with dissolving the API in the cosolvent under closed-vessel conditions in an ISO 5 laminar-airflow hood, followed by pre-filtration through a 0.45 µm membrane and sterilising filtration through a 0.22 µm PVDF membrane; nylon membranes are avoided due to potential cosolvent incompatibility. The filtrate is aseptically filled into 1–5 mL glass vials or polymer syringes under ISO 14644-1:2015 cleanroom conditions and capped using sterile closures. Terminal autoclaving at 121 °C for 15 min is not assumed to be suitable because degradation kinetics for finasteride in this cosolvent system have not been established in public literature; aseptic filtration is the documented method. Quality-release tests include sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788>, and pH measurement in the range 5.0–7.0. The terminal finished dosage type is a sterile solution in 1–5 mL glass vials or prefilled syringes intended for intralesional injection; it is categorically not a systemic intravenous product, and the absence of an FDA-approved injectable finasteride product means each compounded batch must be supported by a beyond-use date derived from site-specific stability data under USP <797>. Operational boundaries include handling finasteride powder as a teratogenic substance with containment controls, restricting preparation to trained personnel, and prohibiting use in PVC infusion bags because cosolvent sorption and leaching data are unavailable. The same injectable format cannot be directly transferred to tablet or capsule manufacturing; the aseptic process train is independent from oral solid-dosage production and requires segregated facilities under 21 CFR 211.42 and 211.167 if produced as licensed sterile product.